-+ 0.00%
-+ 0.00%
-+ 0.00%

Precision BioSciences Q2 net loss widens to $32.65 million; revenue drops to no revenue

PUBT·08/06/2026 11:20:55
Listen to the news
Precision BioSciences Q2 net loss widens to $32.65 million; revenue drops to no revenue
  • Precision BioSciences posted a net loss of USD 32.65 million for the quarter ended June 30, 2026, widening from USD 23.52 million a year earlier.
  • Operating loss narrowed to USD 19.16 million from USD 21.88 million, while total operating expenses fell to USD 19.16 million from USD 21.9 million.
  • Revenue was no revenue versus USD 18,000 a year earlier; research and development costs edged down to USD 12.39 million from USD 12.77 million.
  • General and administrative expense dropped to USD 6.77 million from USD 9.13 million; a USD 13.89 million warrant-liability fair-value loss swung results versus a USD 753,000 gain.
  • Cash, cash equivalents and restricted cash totaled USD 112.4 million at June 30, 2026; management expects funding runway through 2028 with operating discipline and an ATM facility.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precision BioSciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-053837), on August 06, 2026, and is solely responsible for the information contained therein.